Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results , but sales were flat year on year at $1.1 billion. On the ...

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...

Shares of genomics company Illumina (NASDAQ:ILMN) fell 8.6% in the morning session after the company reported fourth-quarter ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

Throughout the last three months, 7 analysts have evaluated Illumina (NASDAQ:ILMN), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of ...

Deep-pocketed investors have adopted a bullish approach towards Illumina (NASDAQ:ILMN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends. Illumina currently has a Zacks Rank #3 (Hold), indicating ...

Investors in Illumina Inc (Symbol: ILMN) saw new options become available today, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ILMN ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the ...

That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target ...